Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients

키워드

참고문헌 (43)

1. Goldhirsch A, "Meeting highlights : international expert consensus on the primary therapy of early breast cancer 2005", Ann Oncol, 16, pp.1569~1583 (2005)
2. Mendelsohn ME, "The protective effects of estrogen on the cardiovascular system", N Engl J Med, 340, pp.1801~1811 (1999)
3. Barrett-Connor E, "Sex differences in coronary heart disease : why are women so superior? The 1995 Ancel Keys Lecture", Circulation, 95, pp.252~264 (1997)
4. Geisler J, "In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients", Clin Cancer Res, 4, pp.2089~2093 (1998)
5. Chlebowski RT, "Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use", Clin Breast Cancer, (6 Suppl 2), pp.S58~S64 (2006)
6. Kannel WB, "Comparison of risk profiles for cardiovascular events : implications for prevention", Adv Intern Med, 42, pp.39~66 (1997)
7. Boring CC, "Cancer statistics, 1994", CA Cancer J Clin, 44, pp.7~26 (1994)
8. Elisaf MS, "Effect of letrozole on the lipid profile in postmenopausal women with breast cancer", Eur J Cancer, 37, pp.1510~1513 (2001)
9. Coates AS, "Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer : update of study BIG 1-98", J Clin Oncol, 25, pp.486~492 (2007)
10. Wasan KM, "The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)", Ann Oncol, 16, pp.707~715 (2005)
11. Goss PE, "Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17", J Natl Cancer Inst, 97, pp.1262~1271 (2005)
12. Arimidex, Tamoxifen, Alone or in Combination (ATAC)Trialists’ Group, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 100-month analysis of the ATAC trial", Lancet Oncol, 9, pp.45~53 (2008)
13. Cuppone F, "Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials", Cancer, 112, pp.260~267 (2008)
14. Amir E, "Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients : a systematic review and meta-analysis", J Natl Cancer Inst, 103, pp.1299~1309 (2011)
15. Lintermans A, "Safety of aromatase inhibitor therapy in breast cancer", Expert Opin Drug Saf, 14, pp.1201~1211 (2015)
16. Herrington DM, "Effects of estrogen replacement on the progression of coronary-artery atherosclerosis", N Engl J Med, 343, pp.522~529 (2000)
17. Katz A, "Quantitative insulin sensitivity check index : a simple, accurate method for assessing insulin sensitivity in humans", J Clin Endocrinol Metab, 85, pp.2402~2410 (2000)
18. Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
19. Polak JF, "Sonographic evaluation of carotid artery atherosclerosis in the elderly : relationship of disease severity to stroke and transient ischemic attack", Radiology, 188, pp.363~370 (1993)
20. Irie Y, "The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease", Diabetes Care, 36, pp.1327~1334 (2013)
21. Winer EP, "American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer : status report 2004", J Clin Oncol, 23, pp.619~629 (2005)
22. Buzdar AU, "Data from the arimidex, tamoxifen, alone or in combination(ATAC)trial : implications for use of aromatase inhibitors in 2003", Clin Cancer Res, 10, pp.355~ (2004)[DOI]
23. Ebrahim S, "Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women : the British Regional Heart Study", Stroke, 30, pp.841~850 (1999)
24. Aydiner A, "Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women", Breast, 22, pp.121~129 (2013)
25. Seruga B, "Association of aromatase inhibitors with coronary heart disease in women with early breast cancer", Cancer Invest, 32, pp.99~104 (2014)
26. Kanters SD, "Reproducibility of in vivo carotid intima-media thickness measurements : a review", Stroke, 28, pp.665~671 (1997)
27. Greenland P, "2010 ACCF", AHA guideline for assessment of cardiovascular risk in asymptomatic adults : a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2010, 56[DOI]
28. Katakami N, "Ultrasonic tissue characterization of carotid plaque improves the prediction of cardiovascular events in diabetic patients : a pilot study", Diabetes Care, 35, pp.2640~2646 (2012)
29. Sharma AM, "A review on carotid ultrasound atherosclerotic tissue characterization and stroke risk stratification in machine learning framework", Curr Atheroscler Rep, 17, pp.55~ (2015)
30. Vigili de Kreutzenberg S, "Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes", Diabetes Care, 38, pp.1937~1944 (2015)
31. Chambless LE, "Carotid wall thickness is predictive of incident clinical stroke : the Atherosclerosis Risk in Communities(ARIC)study", Am J Epidemiol, 151, pp.478~487 (2000)
32. Spence JD, "Carotid plaque area : a tool for targeting and evaluating vascular preventive therapy", Stroke, 33, pp.2916~2922 (2002)
33. Holaj R, "Relation of the thickness of the intima and media of the common carotid artery, atherosclerotic plaque in the carotids and manifestations of atherosclerosis in the vessels of the lower extremity in comparison to coronary atherosclerosis", Cas Lek Cesk, 137, pp.716~720 (1998)
34. Choi BG, "Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model", Atherosclerosis, 201, pp.76~84 (2008)
35. Lamas AZ, "Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats", Life Sci, 124, pp.101~109 (2015)
36. Billon-Gales A, "Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice", Circulation, 120, pp.2567~2576 (2009)
37. Rundek T, "Carotid plaque, a subclinical precursor of vascular events : the Northern Manhattan Study", Neurology, 70, pp.1200~1207 (2008)
38. Zambetti M, "Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation", J Clin Oncol, 19, pp.37~43 (2001)
39. Hooning MJ, "Long-term risk of cardiovascular disease in 10-year survivors of breast cancer", J Natl Cancer Inst, 99, pp.365~375 (2007)
40. Ando F, "Ultrasonic evaluation of common carotid intima-media thickness(IMT) : influence of local plaque on the relationship between IMT and age", J Epidemiol, 10, pp.S10~ (2000)[DOI]
41. Junyent M, "Carotid ultrasound in the assessment of preclinical atherosclerosis : distribution of intima-media thickness values and plaque frequency in a Spanish community cohort", Med Clin(Barc), 125, pp.770~774 (2005)
42. Moskau S, "Heritability of carotid artery atherosclerotic lesions : an ultrasound study in 154 families", Stroke, 36, pp.5~8 (2005)
43. Spence JD, "Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease", Am J Cardiol, 89, pp.10B~15B (2002)

관련 논문AI추천